Sitravatinib 50 mg | 98.90%
TargetMol
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
More Information Supplier PageSitravatinib
Search Results
PHTPP 100 mg | 99.72%
TargetMol
PHTPP
PHTPP 25 mg | 99.72%
TargetMol
PHTPP
PHTPP 10 mg | 99.72%
TargetMol
PHTPP
PHTPP 5 mg | 99.72%
TargetMol
PHTPP
PHTPP 2 mg | 99.72%
TargetMol
PHTPP
Sitravatinib 200 mg | 98.90%
TargetMol
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
More Information Supplier PageSitravatinib
Sitravatinib 100 mg | 98.90%
TargetMol
Sitravatinib (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Axl.
More Information Supplier PageSitravatinib
FX1 2 mg | 99.68%
TargetMol
FX1
Pentostatin 100 mg | 99.47%
TargetMol
Pentostatin is an extremely effective and irreversible inhibitor of adenosine deaminase (Ki: 2.5 pM).
More Information Supplier PagePentostatin
